MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

about

MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

Item

http://www.wikidata.org/entity/Q47428797

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

@en

MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

@nl

type

Item

label

MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

@en

MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

@nl

prefLabel

MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

@en

MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

@nl

P1476

MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

@en

P2093

Ernesto Canalis

http://www.w3.org/2001/XMLSchema#string

P2860

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors

Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait

Effects of PTH on osteocyte function

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

P304

R33-R44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1530/EJE-17-0920

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

178

http://www.w3.org/2001/XMLSchema#string

P50

Ernesto Canalis

P577

2017-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29113980

http://www.w3.org/2001/XMLSchema#string

P921

osteoporosis

P932

5819362

http://www.w3.org/2001/XMLSchema#string